PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
Approximately one-third of CVD patients received PCSK9i at the end of follow-up. The use of PCSK9i was more focused on baseline LDLc concentrations rather than on CVD risk. Women received less PCSK9i in secondary prevention compared to men.
Authors
- Manuel Suárez‐Tembra
- Carlos Morillas (ORCID: https://orcid.org/0000-0002-3745-4423)
- Xavier Pintó (ORCID: https://orcid.org/0000-0002-2216-2444)
- Victoria Marco-Benedí (ORCID: https://orcid.org/0000-0002-7174-0423)
- Rosa M. Sánchez-Hernández (ORCID: https://orcid.org/0000-0003-4991-7445)
- José Luis Díaz-Díaz (ORCID: https://orcid.org/0000-0002-9194-495X)
- Estíbaliz Jarauta (ORCID: https://orcid.org/0000-0001-9142-0737)
- Núria Plana (ORCID: https://orcid.org/0000-0002-4231-7618)
- Fernando Civeira (ORCID: https://orcid.org/0000-0001-7043-0952)
- Juan Pedro‐Botet
Institutions
- Universitat Autònoma de Barcelona (ES)
- Hospital Universitario Insular de Gran Canaria (ES)
- Bellvitge University Hospital (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Universitario Doctor Peset (ES)
- Complexo Hospitalario Universitario A Coruña (ES)
- Hospital Universitari Sant Joan de Reus (ES)
- Hospital Universitario San Rafael (ES)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1186/s12944-024-02283-x
- Citations
- 5
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- European Commission
- Ministerio de Economía y Competitividad
- Gobierno de Aragón
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares
- Instituto de Salud Carlos III
- European Regional Development Fund